A recent study (SOUL trial) found that daily oral semaglutide can reduce the risk of heart attacks, strokes, and cardiovascular death by 14%.
The trial tested Rybelsus, an oral diabetes drug by Novo Nordisk, against a placebo in people with type 2 diabetes already on standard medications.
Semaglutide was approved in 2021 for weight management in people with obesity and related conditions.
The SOUL trial aimed to show that oral semaglutide lowers the risk of major cardiovascular events in people with type 2 diabetes and existing heart or kidney diseases.
Results showed significant reductions in these risks, highlighting semaglutide’s role as the first oral GLP-1 receptor agonist to reduce cardiovascular risks.
The drug’s effectiveness was confirmed even in people already using sodium-glucose cotransporter-2 inhibitor (SGLT2i).
COMMENTS